Use of myo-inositol in women with polycystic ovary syndrome in the application of auxiliary reproductive technologies

• Published in: Medicinskij sovet no. 16; pp. 50 - 56
• Main Authors: Titova, M. S., Kolodina, M. I., Lyashenko, A. S., Lyashenko, E. N.
• Format: Journal Article
• Language: English
• Published: 07-10-2022
• ISSN: 2079-701X; 2658-5790
• DOI: 10.21518/2079-701X-2022-16-16-50-56

   Introduction. 
A large number of treatments for women with PCOS are currently under consideration. Treatment with myo-inositol is one of the new approaches to the treatment of PCOS.
   Aim. 
To study the effect of myo-inositol on the restoration of reproductive function in women with polycystic ovary syndrome using assisted reproductive technologies.
   Materials and methods.
 We conducted a systematic search and analysis of scientific papers in PubMed, MEDLINE, Embase, eLIBRARY, CyberLeninka and Google Scholar using the search PCOS, myo-inositol therapy and assisted reproductive technologies in PCOS terms.
   Results and discussion. 
In the development of PCOS, insulin resistance and hyperandrogenism play a role in 30–40 % of cases. Myo-inositol, which is an endogenous metabolite of the human body, is involved in the synthesis of inositol phosphate derivatives, which are necessary for signal transmission from insulin, GnRH, LH, FSH receptors. This substance helps to increase insulin sensitivity, which can reduce hyperandrogenism and improve the menstrual cycle. We analyzed the literature on the use of MI in women with PCOS with assisted reproductive technologies, since Myo-inositol is effective in normalizing ovarian function, improving the quality of oocytes and embryos in PCOS.
   Conclusion. 
The studies we examined show improvements in ovarian function, oocyte and embryo quality in patients taking myo-inositol combined with other drugs. However, further examination of large multicenter, randomized, controlled studies are needed to evaluate pregnancy and live births, as there are sources that do not confirm the efficacy of myo-inositol therapy.